A Study of LY3314814 in Participants With Liver Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

NCT05916560

Healthy Hepatic Insufficiency

COMPLETED PHASE1

A Study of Two Different Formulations of LY3209590 in Healthy Participants

NCT04768842

Healthy

COMPLETED PHASE1

A Study of LY3314814 in Healthy Participants

NCT03222427

Healthy

COMPLETED PHASE1

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

NCT01836185

Hepatic Insufficiency

COMPLETED PHASE1

A Study of LY3023414 Formulations and the Effect of Food

NCT02818335

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3314814 Control

LY3314814 administered orally to participants with normal hepatic function

Group Type EXPERIMENTAL

LY3314814

Intervention Type DRUG

Administered orally

LY3314814 Mild

LY3314814 administered orally to participants with mild hepatic impairment

Group Type EXPERIMENTAL

LY3314814

Intervention Type DRUG

Administered orally

LY3314814 Moderate

LY3314814 administered orally to participants with moderate hepatic impairment

Group Type EXPERIMENTAL

LY3314814

Intervention Type DRUG

Administered orally

LY3314814 Severe

LY3314814 administered orally to participants with severe hepatic impairment

Group Type EXPERIMENTAL

LY3314814

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3314814

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening

Exclusion Criteria

* Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina
* Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation
* Have acute unstable neuropsychiatric disease
* Have active or uncontrolled neurologic disease, or clinically significant head injury

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes